Literature DB >> 8409040

Economics of elective coronary revascularization. Comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery.

D J Cohen1, J A Breall, K K Ho, R M Weintraub, R E Kuntz, M C Weinstein, D S Baim.   

Abstract

OBJECTIVES: This study was designed to evaluate more closely the true in-hospital costs of elective revascularization by directional coronary atherectomy and intracoronary stenting and to compare these costs with those of the traditional revascularization alternatives (i.e., conventional balloon angioplasty and coronary artery bypass surgery).
BACKGROUND: Previous studies have suggested that total hospital charges for directional coronary atherectomy or intracoronary stenting are significantly higher than those for conventional angioplasty. However, hospital charges do not necessarily reflect true economic costs, and their use may provide misleading data with regard to cost-effectiveness.
METHODS: We analyzed in-hospital charges from the itemized hospital accounts of 300 patients undergoing elective angioplasty, directional atherectomy, Palmaz-Schatz coronary stenting or bypass surgery between January 1, 1990 and December 31, 1991. Costs were then derived by adjusting itemized patient accounts for department-specific cost/charge ratios. Catheterization laboratory costs were based on actual resource consumption, and daily room costs were adjusted for the intensity of nursing services provided.
RESULTS: Length of hospital stay was similar for atherectomy (2.3 +/- 1.5 days) and conventional angioplasty (2.6 +/- 1.7 days) but significantly longer for stenting (5.5 +/- 2.6 days, p < 0.05). Total costs were also significantly higher for coronary stenting ($7,878 +/- $3,270, median $6,699, p < 0.05) than for angioplasty ($5,396 +/- $2,829, median $4,753) or atherectomy ($5,726 +/- $2,716, median $4,986). However, length of stay, resource consumption (laboratory and radiologic testing, drugs, blood products, for example) and total costs for bypass surgery were still greater than for any of the percutaneous interventional procedures.
CONCLUSIONS: In contrast to previous studies utilizing only hospital charges, the in-hospital costs of angioplasty and directional coronary atherectomy were similar. Although the cost of coronary stenting was approximately $2,500 higher than that of conventional angioplasty, the magnitude of this difference was smaller than the $6,300 increment previously suggested on the basis of analysis of hospital charges. These findings reflect the inherent discrepancies between cost-based and charge-based methodologies and may have important implications for future studies evaluating the relative cost-effectiveness of newer coronary interventions.

Entities:  

Mesh:

Year:  1993        PMID: 8409040     DOI: 10.1016/0735-1097(93)90415-w

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  13 in total

1.  A decision chart for assessing and improving the transferability of economic evaluation results between countries.

Authors:  Robert Welte; Talitha Feenstra; Hans Jager; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  A review of health care models for coronary heart disease interventions.

Authors:  K Cooper; S C Brailsford; R Davies; J Raftery
Journal:  Health Care Manag Sci       Date:  2006-11

3.  The performance and publication of cost-utility analyses in plastic surgery: Making our specialty relevant.

Authors:  Achilleas Thoma; Teegan A Ignacy; Natalia Ziolkowski; Sophocles Voineskos
Journal:  Can J Plast Surg       Date:  2012

4.  In Brief: cost-effectiveness analyses in orthopaedics.

Authors:  Patrick Vavken; Thomas Bianchi
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

5.  Cost-effectiveness of coronary interventions.

Authors:  D J Cohen; C A Sukin
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

Review 6.  A primer of biostatistic and economic methods for diagnostic and prognostic modeling in nuclear cardiology: Part II.

Authors:  L J Shaw; E L Eisenstein; R Hachamovitch; G V Heller; D D Miller
Journal:  J Nucl Cardiol       Date:  1997 Jan-Feb       Impact factor: 5.952

7.  Direct costs of coronary artery bypass grafting in patients aged 65 years or more and those under age 65.

Authors:  G Naglie; C Tansey; M D Krahn; K O'Rourke; A S Detsky; H Bolley
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

8.  The economic burden of complications during percutaneous coronary intervention.

Authors:  Kurt M Jacobson; Kirsten Hall Long; Erin K McMurtry; James M Naessens; Charanjit S Rihal
Journal:  Qual Saf Health Care       Date:  2007-04

Review 9.  Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.

Authors:  C J Dunn; R H Foster
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

10.  Electrochemical and microstructural studies of tantalum and its oxide films for biomedical applications in endovascular surgery.

Authors:  R A Silva; M Walls; B Rondot; M Da Cunha Belo; R Guidoin
Journal:  J Mater Sci Mater Med       Date:  2002-05       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.